Background: In a 72-week, randomised controlled trial of obeticholic acid (OCA) in
45% patients in the OCA group compared to only 21% in the placebo group achieved the pre-defined improvement in liver histology (P = 0.0002). Treatment with OCA improved all features of NAS (steatosis, hepatocellular ballooning, and lobular inflammation) as well as hepatic fibrosis. Histological resolution of NASH, however, occurred in only 19% of OCA-treated vs 13% of placebo recipients, a difference that was not statistically significant. Importantly, OCA therapy was also associated with weight loss, with average weight decreasing by 2.3 kg by week 72 in the OCA group compared to no change (0.0 kg) with placebo.
Since weight loss can improve clinical and metabolic features of NASH, this secondary analysis aim was to evaluate the effects of weight loss and OCA treatment (vs placebo) in improving clinical and metabolic features of NASH.
| STUDY METHODS

| FLINT trial
The FLINT trial was a prospective, double-blind randomised trial of OCA vs placebo in 283 adult patients with histologically defined non-alcoholic steatohepatitis. The aims, design and primary outcomes of this trial have been published. 14 Briefly, subjects underwent a clinical evaluation, including liver biopsy, and those with histological features of NASH and a NAS score of at least 4
(on a scale of 0-8) were randomised to receive either OCA (25 mg) or identical appearing placebo tablets once daily for 72 weeks. All patients were followed with visits and routine blood tests at 12-week intervals and repeat liver biopsy at the end of the 72 weeks of treatment. In this trial, the final 64 patients did not undergo a follow-up liver biopsy because a pre-planned interim analysis showed a highly significant difference in the primary endpoint after completion of therapy in the initial 219
patients. For this reason, therapy was stopped early and subjects still in study were followed up for another 24 weeks on no treatment. The study was conducted between 2011 and 2013 at eight US medical centres and the data were managed by a central Data
Coordinating Center (the names of the medical centres, data coordinating centre and principal investigators are provided in the Appendix 1). All patients gave written informed consent and details of the trial were approved by local institutional review boards. In addition, the design, protocol, details and conduct of the trial were monitored by an independent data safety and monitoring board appointed by the funding source, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.
| Post hoc subgroup analysis
This post hoc subgroup analysis focused on weight change in patients who received OCA or placebo and the association of these changes with changes in histological features, serum enzymes, metabolic factors and adverse events and was limited to patients who underwent repeat liver biopsy at 72 weeks. The changes in body weight between baseline and week 72 were categorised into two strata (1) weight loss (2% or more); (2) no weight loss (<2% loss or weight gain), as done in previous analyses of trials of therapy in NASH. 15 In comparing baseline and 72 week liver biopsies, histological improvement was defined as a 2-point or greater decrease in NAS with no worsening of fibrosis. Changes in serum enzymes, lipids and biochemical features of insulin sensitivity in association with weight change in both groups were also evaluated. Finally, changes in LDL cholesterol at 72 weeks by treatment group and weight loss category were evaluated in relation to statin use.
All liver biopsies were scored for features of NAFLD and NASH using a standardised scoring system by the Pathology Committee of the NASH CRN. 16 The NAFLD activity score (NAS) comprised the combination of scores given for steatosis (0-3), lobular inflammation (0-3) and ballooning degeneration (0-2). Fibrosis stage ranged from 0 to 4 with stage 3 representing bridging fibrosis and Stage 4 cirrhosis.
Details of the scoring system, including its intra-and inter-observer variation, have been described previously.
14,16
| Statistical analysis
Comparison of baseline characteristics between patients with vs without 72-week biopsies were assessed using the t test for continuous variables and the chi-square test for categorical variables.
Changes from baseline were assessed for the entire study cohort and also between two groups with and without weight loss as defined above. In addition, the interaction of treatment group and weight loss was assessed in a separate model for each outcome vari- patients with ≥2% weight loss at 72 weeks had higher mean alkaline phosphatase (P = 0.02), lower HDL (P = 0.03) and lower usage of Vitamin E (P = 0.005) ( Table 1) .
During the 72 weeks of therapy, patients on OCA lost an average of 2.3 kg compared to 0.0 kg in the placebo group. The amount of weight change varied among individuals in both groups and was ≥2% loss in 44% of the OCA compared to 32% in the placebo group (P = 0.08). The distribution of percent change in weight at the 12-week intervals during the course of the FLINT trial in the OCA and placebo groups are shown in Figure 1 . As compared to patients on Placebo, a higher proportion of patients on OCA had ≥2% weight loss starting at week 12 and continuing throughout follow-up and during the 24 weeks after stopping treatment. Table 2 shows the joint effects of OCA and weight loss on 72-week changes from baseline in liver tests, liver histology, lipids, metabolic factors and adverse effects.
| Weight change and liver enzymes
ALT levels decreased in patients receiving OCA and to a somewhat greater degree in those who lost weight (À43 U/L) than in those who did not (À34 U/L) (P = 0.12) ( Table 2) . Similarly, among patients receiving placebo, decreases in ALT levels were greater in patients with weight loss (À29 U/L) compared to those without (À10 U/L) (P = 0.02). Upon stopping treatment, ALT levels rose in the OCA treated patients but not in those who had received placebo (data not shown). Improvements in AST followed a similar pattern, being greater in patients receiving OCA, but also being more marked in those with weight loss in both groups (Table 2 ) and upon stopping treatment, AST levels rose in OCA-treated patients but not in those who received placebo ( Figure 2 ). Thus, both OCA and weight loss appeared to improve serum aminotransferase levels, and the effects appeared to be additive.
Alkaline phosphatase levels demonstrated a different and paradoxical pattern of change, in that they increased with OCA therapy and most markedly in those with weight loss (+21 U/L) compared to those without weight loss (+6 U/L) ( Table 2 ). In contrast, alkaline phosphatase levels decreased in patients on placebo, the degree of change being greater in those who lost weight (À12 U/L) than those who did not (À5 U/L) (interaction P<0.001). The percentage of patients with levels above the upper limit of normal (defined as >115 U/L) at baseline for OCA and placebo were 10% and 9%, respectively, and at the end of treatment for OCA and placebo were 24% and 4%, respectively (data not shown; P<0.0001).
| Weight change and liver histology
The primary outcome, a histological improvement of at least 2 points in the NAS score without worsening of fibrosis was achieved in 49%
of OCA treated and 23% of placebo treated patients in this analysis (P<0.001) similar to what was shown in the full cohort. 14 However, this outcome was more frequent in patients who lost vs did not lose weight (Table 2 ); in both the OCA (64% vs 37%, P = 0.006) and placebo-treated patients (32% vs 19%, P = 0.17). With or without weight loss, the proportion achieving this outcome was greater in the OCA than the placebo treated patients. These relationships were also reflected in the total NAS which changed more in the patients who lost vs did not lose weight, both in the OCA treated (À2.4 vs À1.2 points, P<0.001) and the placebo group (À1.2 vs À0.5 points, P = 0.03), with change being greater in the OCA treated patients.
Analysis by individual components of the NAS showed a similar pattern of change, being greater among those who lost weight in both treatment groups, but also overall being greater in the OCA group.
Changes in fibrosis stage were greater in the OCA treated patients and the greatest change occurred in patients on OCA who lost weight (À0.3 vs À0.1 stages, P = 0.20). Collectively, these results suggested that both OCA treatment and weight loss significantly improved activity scores in NASH and that the effects were additive.
| Weight change and serum glucose and insulin change in nondiabetics
Since evaluation of serum glucose, insulin and HOMA-IR in patients with diabetes is confounded with anti-diabetic treatment, we excluded people with diabetes (n = 107) in the analysis of these factors. In the placebo group, fasting serum glucose levels decreased among those who lost weight, but not in those who did not (À13.7 Fibrosis was assessed on a scale of 0 to 4, with higher scores indicating more severe fibrosis. The Nonalcoholic fatty liver disease activity score (NAS) was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure are steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). | 649 vs 3.7 mg/dL; P<0.001) ( Table 2) . A similar pattern was found in the placebo group for insulin levels (À5.4 vs 4.4 umol/mL; P = 0.002) and HOMA-IR (À1.8 vs 1.3 mg/dL 9 umol/mL/405; P = 0.002) decreasing with weight loss but not without. A similar weight loss effect was seen in the OCA patients; but as compared to those on placebo, OCA patients had significantly higher net effects for changes in fasting serum glucose (+6.8 mg/dL; P = 0.006) (Table S1 ), insulin (+6.6 umol/mL; P = 0.02) and HOMA-IR (+1.9; P = 0.01).
There were no interaction effects; thus indicating additive positive effects of weight loss but negative effects of OCA on changes in serum glucose, insulin and HOMA-IR.
| Weight change and other metabolic effects
Changes in other metabolic factors during therapy often were discrepant between the groups in a pattern that resemble the paradoxical changes in alkaline phosphatase ( Table 2 ). As would be expected, total serum cholesterol levels decreased significantly in the placebo patients who lost weight (À14 mg/dL) compared to those who did not (0 mg/dL). In contrast, total serum cholesterol levels increased significantly in patients taking OCA who lost weight (+13 mg/dL) but less so in patients on therapy in those who did not lose weight (+2 mg/dL) (interaction P = 0.02). LDL cholesterol levels followed a similar paradoxical pattern, with LDL cholesterol increasing (+18 mg/ dL) in OCA patients who lost weight, while decreasing in the placebo patients who lost weight (À12 mg/dL) with mean values changing little or not at all in those who did not lose weight in both OCA and placebo groups (interaction P = 0.01). Serial mean serum LDL cholesterol levels in the patients who did and did not lose weight are displayed in Figure 2 separately for the OCA and placebo groups. The LDL cholesterol levels rose within the first 12 weeks of treatment with OCA and then decreased back to baseline in those who did not lose weight, but remained elevated in those on OCA who lost weight, these effects resolving within 24 weeks of stopping treatment. Waist circumference decreased in both OCA (P = 0.006) and placebo groups (P<0.001) among patients who lost weight vs those with no weight loss whereas the waist to hip ratio did not change in the OCA group (P = 0.77) but did in the placebo group (P = 0.06). In placebo patients, mean haemoglobin A1c values decreased by À0.4% in those who lost weight vs increased by +0.2% in those who did not lose weight (Figure 2 ). In contrast, in OCA patients, the mean haemoglobin A1c levels did not change regardless of weight loss (+0.1% in both groups) (interaction P = 0.01).
Statin therapy for hypercholesterolaemia was permitted and indeed encouraged if present, although the specific therapy was left to the discretion of the primary physician and was not dictated by a FLINT trial protocol. The possible role of statin therapy on changes in LDL cholesterol was assessed by comparing changes in LDL cholesterol levels in the two treatment groups by weight loss stratum and whether statins were used, added or withdrawn during the study (Table 3 ). In all categories of statin use, LDL cholesterol levels increased more in OCA treated patients who lost weight than in those who did not whereas levels decreased more in placebo recipients who lost weight in comparison to those who did not. This paradoxical effect of change in LDL cholesterol by treatment group and weight loss did not vary by statin use (P = 0.66).
| Adverse events
Finally, side effects that were more frequent in the OCA than placebo-treated patients (pruritus and gastrointestinal symptoms) but did not differ by weight loss category (Table 2 ). This post hoc analysis showed that the OCA and weight loss had additive effect in improvements of histology and serum aminotransferase levels. The group achieving the most impressive improvements in both histology and reduction in ALT and AST was the OCA-treated cohort with weight loss. Of note, results were similar when weight change was categorised into three groups, with an additional group for 2+ kg weight gain (data not shown). Indeed, the primary outcome of histological improvement without fibrosis progression occurred in 64% of patients on OCA who lost 2% or more during the 72 weeks of treatment compared to 37% of those on OCA who did not lose weight; 32% of placebo recipients who lost weight; and 19% of placebo patients who did not lose weight).
Changes in fibrosis stage were greater in the obeticholic acid treated patients with greatest change in patients who also lost weight suggesting effects of both obeticholic acid treatment and weight loss were additive. These results highlight the important contribution of weight loss to improvements in histology and the importance of having untreated control patients in clinical trials of new therapeutics. More importantly, this study uniquely highlights the potential for additive effects between lifestyle measures and novel therapies, such as obeticholic acid.
Equally striking were the paradoxical and antagonistic effects of OCA and weight loss on lipids and other metabolic factors. Thus, the benefits of weight loss on improving cholesterol levels and haemoglobin A1c seen in placebo patients with weight loss were not seen in patients on OCA with weight loss. This was unexpected. One clue might be the changes in waist circumference and waist/hip ratios seen in the two groups. The decrease in waist/hip ratio that occurred in placebo recipients, who lost weight, was not seen in the OCA recipients with weight loss (interaction P = 0.22), suggesting that weight loss on OCA is Predominantly peripheral fat whereas weight loss occurring in the absence of OCA is largely from the central compartment which is more metabolically active. This hypothesis, however, is based on indirect information and future studies incorporating assessment of changes in fat distribution during OCA therapy should be considered.
Weight loss with OCA therapy has not been reported in treatment studies of patients with primary biliary cholangitis. 19 The mechanism underlying this weight loss in patients with NASH is unknown but FXR It is well established that FXR activation causes reduction in bile acid synthesis by inhibiting the conversion of cholesterol to bile acids which is a major mechanism of cholesterol disposal. Blocking the conversion of cholesterol to bile acids potentially could increase serum cholesterol concentrations, which might explain the changes in serum cholesterol concentrations seen with OCA treatment.
Moreover, the FXR agonists may also promote reverse cholesterol transport out of tissues. 20, 21 Striking in our analysis was the interactive but negative effects of weight loss and OCA on cholesterol levels, with the weight loss group experiencing the greater increase in cholesterol on treatment.
The limitations of this analysis need to be considered. First, the study had a modest sample size, particularly when analysing subgroups of the treatment cohorts and weight categories. In addition, changes in cholesterol, glucose and body weight may well have been due to other unmeasured factors active in this study. Perhaps most importantly, the administration and dose of statins were not standardised and only limited information on statin use was obtained during the trial. Thus, whether a statin was being taken was documented, but changes in dose or the duration of treatment were not.
Nevertheless, the consistent pattern of discrepancy between the two treatment groups in response to weight loss was striking and calls for larger prospective studies with more accurate measures of lipids and blood glucose levels and longer duration of follow-up.
These analyses also serve as a reminder that NASH is a systemic condition and that treatment of the liver disease cannot be done independent of monitoring and managing other components of the metabolic syndrome. 
